The time period indicated by the Sun Pharma share price target analyst is one year during which Sun Pharmaceutical Industries Ltd price may attain a specific target. Sun Pharmaceutical Industries Ltd., incorporated in 1993, is a Large Cap (having a market cap of Rs 195,641.77 Crore) operating in Pharmaceutical sector. Sun Pharmaceuticals Industries Limited had traded with a gain of 2.91% at 838.80 on the NSE last time. Sun Pharmaceutical Industries share price is on an upward trend, so we believe similar market segments have been very popular over time. ICICI Securities has bought buyback shares of Sun Pharmaceutical Industries with a target price of Rs 959.
Sun Pharma Share Price Target
The stock is trading above the weekly resistance and downside can be expected only if it trades below 820.13. Sun Pharmaceuticals Industries Ltd. Sun Pharma’s outlook for tomorrow’s activity as on December 29, 2021 looks optimistic. Shares of Sun Pharmaceutical Industries touched a five-year high of Rs 846.80, up 2% on BSE on Wednesday; Revenue growth is expected to remain significant on the back of intraday trading, good expertise and strong domestic performance. Sun Pharma Stock Price Forecast for the Day and Tomorrow – Using the MACD Indicator Sun Pharma Stock Price Forecast Using the MACD Indicator See if you need to buy, sell or hold those shares in order to trade.
Similarly, you can buy Sun Pharma at current market price with a target of Rs 880 to Rs 920 while placing a stop loss at Rs 804. Check daily Sun Pharma stock price target for intraday and Sun Pharma stock price forecast for tomorrow. -Term trading and long term investment. Sun Pharma Stock Price Prediction or Target – Using Camarilla Equation View intraday, tomorrow and short term forecast of Sun Pharma stock price using Camarilla Equation.
CLSA retained its buy rating for Sun Pharma after its September quarter results, but raised its 12-month target price to Rs 1,050 from Rs 960. Citigroup retained its buy rating for Sun Pharma after the second quarter results and raised the target to Rs 1,000.
Sun Pharma Share Price Targets 2022, 2023, 2024, 2025 and 2030
The complaint alleges that parent company Sun is responsible for Ranbaxy, and that Ranbaxy through a series of misstatements and omissions has been able to suspend the business of all counterfeit versions of Valcyte, Dewan and Nexium for several years. received incorrectly. He gives buy advice on Dr Reddy’s, Sun Pharma, Cipla and Divis Labs today. Investors can start buying Dr. Reddy’s at current market price with a maximum target of Rs 5,340 and a stop loss of Rs 4,970. The sales risk of Sequa still exists, and similar Restasis products may be produced,” the brokerage firm said in its updated list.
According to Graham’s internal equation, you should invest in stocks if the current share price is low. This indicator helps the trader to estimate the stock price and trade accordingly. Breaking news is gathered from a variety of sources and can have a positive or negative effect on stock prices in the short term.
Main Products Segment / Revenue Sun Pharmaceutical Industries Ltd. consists of pharmaceutical and other operating revenues for the year ended 31st March-2021. Some pharmaceutical stocks have been sold and according to experts, they can be bought for further growth in the next 2-3 months. We rate V-Guard at 35x P/E per share as on June 23 to achieve target price of Rs 265.
Sun’s strong (net cash) balance sheet is likely to fuel special spending and non-organic initiatives. We have increased our TP/SOTP to Rs.1,800 to accommodate potential gains from value addition and new business development. Sun Pharmaceuticals Industries Ltd. Sun Pharma’s forecast for December 29, 2021 shows signs of strength. Sunpharmaceuticals’ target estimates for February 2022 are 841.55, 808.48, 775.4 up and 665.65, 698.73, 731.8 down.
SunPharmaceuticals’ target forecasts for Friday, February 11, 2022 are 916.53, 857.44, 798.34 and 654.27, 713.37, and 772.46, respectively. The flagship company Reliance Industries Limited is a Fortune Global 500 company and the largest private company in India. The company reported net income after tax of Rs 2,088.73 in the most recent quarter. From September 30, 2021 to 2021, the founder holds 54.48% of the company’s capital, while FII holds 12.07% and DII holds 21.72%.
However, given judicious evaluation, we reiterate the decision as all positives are judged objectively. Low to moderate single-digit portfolio price growth was necessary to counter inflation and maintain margins. The company reported net income after tax of Rs 2,088.73 in the most recent quarter.
Since big caps are important to you, here is our bluechip stock buying guide. Currently, there appears to be a trend where stocks were popular across sectors during this period.
LKP Wealth Advisory Limited is registered as an Investment Consultancy Company by Securities Board of India, SEBI Registration No. Our customers, third parties or any other person is not authorized, at our choice, to forward or transmit, directly or indirectly, any other information we provide.
Marketing efforts support Illumya’s strong performance: FY21 reported 51% y/y sales of specialty products Ajanta Pharma reported strong numbers for FY 2Q22 which beat sales forecast.
Strong sales of livelihoods have resulted in the ratio of unsold stocks with LPG to low-level reserves, which currently have a year’s supply to sell their livelihoods. The pharmaceutical company reported a pre-tax profit of Rs 1,804.2 crore in Q1 FY22 as compared to a pre-tax loss of Rs 283.9 crore in Q1 FY21.
Sun Pharma’s research and development division comprises approximately 2,000 scientists, and investments account for about 8% of annual revenue. In Q2 FY22, Sun Pharma reported excellent results for Q2 FY22, with sales up 12.5% YoY to Rs.
The performance data provided represents past results and does not guarantee future results. Nothing contained in this document is an offer to sell or a call to buy any security.
Its main target markets include India, Russia, Romania, Nigeria, South Africa and Myanmar. On the EBITDA margin, management expects to maintain the current rate in FY22. Its production units are located in, among others, India, USA and Brazil.
- Indigo Share Price Targets 2022, 2023, 2 2024, 2025 and 2030
- INOX Share Price Targets 2022, 2023, 2024, 2025 and 2030
- SpiceJet share price target 2022, 2023, 2024, 2025 and 2030
- HFCL Share Price Targets 2022, 2023, 2024, 2025 and 2030
- RBL Bank Share Price Target 2022, 2023, 2024, 2025, 2026 and 2030
- HP Adhesives Share Price Targets 2022, 2023, 2024, 2025 and 2030
- Recent share price targets 2022, 2023, 2024, 2025 and 2030
- Subex Share Price Target 2022, 2023, 2024, 2025, 2030 – Multibagger Stock!
- Zomato Share Price Target 2022, 2023, 2024, 2025 and 2030
- Ethereum Price Targets 2022, 2023, 2024, 2025 and 2030
- GreenPanel Share Price Targets 2022, 2023, 2024, 2025 and 2030
- Bitcoin Price Prediction 2021, 2022, 2023, 2024 and 2025
- Adani Enterprises Share Price Target 2022, 2023, 2024 and 2025
- Tata Motors Share Price Target 2022, 2023, 2024, 2025, 2030
- ICICI Bank Share Price Target 2022, 2023, 2025, 2030
- Paytm Share Price Target 2022, 2023, 2024, 2025 and 2030
- Reliance Share Price Target 2022, 2023, 2025, 2030
- DMart Share Price Target 2022, 2023, 2024, 2025 and 2030
- 3i Infotech Share Price Targets 2022, 2023, 2024, 2025 and 2030
- Tata Power Share Price Target 2022, 2023, 2024, 2025, 2030
- Incognito View Analytics Share Price Targets 2022, 2023, 2024, 2025 and 2030